CROs Confront Challenges as Biotech Market Slows
In a recent analysis, Jefferies is advising investors to rethink their investments in contract research organizations (CROs), particularly those focused on biotech and early-stage research. This caution comes as the demand in the biotech sector has noticeably declined.
Financial Struggles Affects Companies
Jefferies has notably changed its outlook on Fortrea (FTRE) and Medpace Holdings (NASDAQ: MEDP), downgrading them from a Buy to a Hold rating. This shift comes as a result of growing financial challenges and budget cuts affecting the industry.
Budget Reductions and Market Impact
According to Jefferies, CROs are facing significant obstacles as pharmaceutical and biotech companies tighten their financial belts. These changes reflect a wider trend where funding for biotech projects is declining steeply.
Insights on Medpace and Fortrea
Medpace is particularly exposed, with an astonishing 80% of its revenue coming from small biotech companies. Conversely, Fortrea's deep commitment to early-phase research puts it at increased risk in this tough climate.
Negative Feedback from CROs
Jefferies has noted that increasing bad debts and budget cuts have led to worsening remarks from CROs throughout this quarter. This trend emphasizes that the downturn in biotech funding, which began in recent years, now substantially affects CRO operations, resulting in more project cancellations and fewer new initiatives.
Future Performance Outlook
The outlook for Fortrea is particularly concerning; its growth strategy relies on boosting revenue to meet margin goals. However, analysts at Jefferies are doubtful about the company's chances of reaching its 2025 EBITDA margin target due to decreasing bookings, which are expected to hinder revenue growth next year.
Medpace's Evolving Revenue Landscape
While Medpace had previously been able to grow its revenue despite the decline in biotech funding, it's now starting to feel the impact of cancellations. Jefferies predicts that Medpace’s bookings-to-billings ratio for the third quarter will likely fall to the lower end of its target range, which could negatively influence its earnings in 2025.
Valuation Challenges Ahead
In summary, Jefferies points out that both Medpace and Fortrea are under pressure regarding their valuations. Their declining fundamentals are at odds with their high valuations compared to industry peers. The firm warns that this pattern may lead to further declines in stock prices for these companies.
Frequently Asked Questions
What is Jefferies' recommendation regarding CROs?
Jefferies suggests that investors should reduce their exposure to CROs due to declining demand in the biotech sector.
Which companies did Jefferies downgrade?
Jefferies downgraded Fortrea and Medpace Holdings, shifting their ratings from Buy to Hold.
Why is Medpace considered vulnerable?
Medpace is seen as vulnerable because it relies on small biotech firms for 80% of its revenue, making it sensitive to shifts in the industry.
What challenges does Fortrea currently face?
Fortrea’s growth strategy relies heavily on increasing revenue, which is challenging under the current economic conditions.
What does the future hold for these companies according to Jefferies?
Jefferies anticipates that both Medpace and Fortrea will face further valuation pressures due to their weakening fundamentals.
